Emedastine Difumarate
FDA-approved product (solution/drops, ophthalmic), marketed as Emadine.
- Registered studies
- 2
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Allergic conjunctivitis
- Eye allergy
Indications ChEMBL records as approved, from FDA and DailyMed labels.
- WHO therapeutic group
- Other antiallergics
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli33.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
2registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Emedastine Difumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells41.4% AI-predicted activityagainst K. pneumoniae10 registered studies
- Ergotamine TartrateExisting use: Headache, Migraine disorder41.3% AI-predicted activityagainst K. pneumoniae10 registered studies
- InavolisibExisting use: Breast cancer, Breast neoplasm41.2% AI-predicted activityagainst K. pneumoniae36 registered studies
- Rimegepant SulfateExisting use: Migraine disorder40.9% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pasireotide PamoateExisting use: Acromegaly, Pituitary-dependent Cushing's disease40.9% AI-predicted activityagainst K. pneumoniae1 registered study
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia40.9% AI-predicted activityagainst K. pneumoniae41 registered studies
- Avatrombopag MaleateExisting use: Hemorrhage, Liver disease, Thrombocytopenia40.8% AI-predicted activityagainst K. pneumoniae6 registered studies
- LinagliptinExisting use: Diabetes mellitus, Type 2 diabetes mellitus40.6% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Rocuronium BromideExisting use: Other quaternary ammonium compounds40.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BiotinExisting use: Anemia (phenotype), Chronic kidney disease, Iron deficiency anemia and 1 more40.3% AI-predicted activityagainst K. pneumoniae50+ registered studies
- BuprenorphineExisting use: Chronic pain, Drug dependence, Opioid dependence and 4 more40.2% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Vinorelbine TartrateExisting use: Cancer, Neoplasm40.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Efficacy of Artemisia Pollen Specific Allergen Immunotherapy
NCT05318157 · start 2022-03-31
Registered record
- Registry ID
- NCT05318157
- Conditions
- Allergic Rhinitis
- Interventions
- AIT drops; Clarityne, Rhinocort and Emedastine Difumarate Eye Drops
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Unknown
- Start
- 2022-03-31
- Completion
- 2024-11-30
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic RhinitisInterventionAIT drops; Clarityne, Rhinocort and Emedastine Difumarate Eye DropsPhasePhase 4Registry statusUnknownKetotifen Ophthalmic Solution With Emedastine in Patients With Seasonal Allergic Conjunctivitis
NCT00133627 · start 2005-04
Registered record
- Registry ID
- NCT00133627
- Conditions
- Seasonal Allergic Conjunctivitis
- Interventions
- Ketotifen
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2005-04
- Completion
- 2005-10
- Enrolment
- 229
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionSeasonal Allergic ConjunctivitisInterventionKetotifenPhasePhase 4Registry statusCompleted